AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity
AMP-activated protein kinase (AMPK) is a metabolic fuel gauge conserved along the evolutionary
scale in eukaryotes that senses changes in the intracellular AMP/ATP ratio 1 . Recent …
scale in eukaryotes that senses changes in the intracellular AMP/ATP ratio 1 . Recent …
[HTML][HTML] Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α
…, F Daussin, N Messadeq, J Milne, P Lambert, P Elliott… - Cell, 2006 - cell.com
Diminished mitochondrial oxidative phosphorylation and aerobic capacity are associated with
reduced longevity. We tested whether resveratrol (RSV), which is known to extend lifespan…
reduced longevity. We tested whether resveratrol (RSV), which is known to extend lifespan…
Proteasome inhibitors: a novel class of potent and effective antitumor agents
…, DD Lazarus, J Maas, CS Pien, S Prakash, PJ Elliott - Cancer research, 1999 - AACR
The ubiquitin-proteasome pathway plays a critical role in the regulated degradation of proteins
involved in cell cycle control and tumor growth. Dysregulating the degradation of such …
involved in cell cycle control and tumor growth. Dysregulating the degradation of such …
Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes
…, DA Sinclair, JM Olefsky, MR Jirousek, PJ Elliott… - Nature, 2007 - nature.com
Calorie restriction extends lifespan and produces a metabolic profile desirable for treating
diseases of ageing such as type 2 diabetes 1 , 2 . SIRT1, an NAD + -dependent deacetylase, …
diseases of ageing such as type 2 diabetes 1 , 2 . SIRT1, an NAD + -dependent deacetylase, …
The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells
…, P Richardson, D Chauhan, VJ Palombella, PJ Elliott… - Cancer research, 2001 - AACR
Human multiple myeloma (MM) is a presently incurable hematological malignancy, and novel
biologically based therapies are urgently needed. Proteasome inhibitors represent a novel …
biologically based therapies are urgently needed. Proteasome inhibitors represent a novel …
[PDF][PDF] Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span
…, A Csiszar, Y Ikeno, D Le Couteur, PJ Elliott… - Cell metabolism, 2008 - cell.com
A small molecule that safely mimics the ability of dietary restriction (DR) to delay age-related
diseases in laboratory animals is greatly sought after. We and others have shown that …
diseases in laboratory animals is greatly sought after. We and others have shown that …
[BOOK][B] Probabilistic number theory I: Mean-value theorems
PDTA Elliott - 2012 - books.google.com
… For an alternative treatment see the author's paper (Elliott [16]). In fact a satisfactory analysis
of the limiting behaviour of the frequencies (10) may be carried out assuming only that the …
of the limiting behaviour of the frequencies (10) may be carried out assuming only that the …
Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies
…, S Stahl, J Adams, DL Esseltine, PJ Elliott… - Journal of Clinical …, 2002 - ascopubs.org
PURPOSE: To determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), and
pharmacodynamics (PD) of the proteasome inhibitor bortezomib (previously known as PS-…
pharmacodynamics (PD) of the proteasome inhibitor bortezomib (previously known as PS-…
[HTML][HTML] Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation
…, SM Houten, JC Milne, PD Lambert, C Mataki, PJ Elliott… - Cell metabolism, 2008 - cell.com
The NAD + -dependent deacetylase SIRT1 controls metabolic processes in response to low
nutrient availability. We report the metabolic phenotype of mice treated with SRT1720, a …
nutrient availability. We report the metabolic phenotype of mice treated with SRT1720, a …
Systematic discovery of multicomponent therapeutics
AA Borisy, PJ Elliott, NW Hurst… - Proceedings of the …, 2003 - National Acad Sciences
Multicomponent therapies, originating through deliberate mixing of drugs in a clinical setting,
through happenstance, and through rational design, have a successful history in a number …
through happenstance, and through rational design, have a successful history in a number …